Akero Therapeutics, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
AKRO Company Description
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
AKRO Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view AKRO Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of AKRO by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by AKRO's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of AKRO in WallStreetBets Daily Discussion
AKRO News
Recent insights relating to AKRO
CNBC Recommendations
Recent picks made for AKRO stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in AKRO
Corporate Flights
Flights by private jets registered to AKRO
Our Analysis